Intravitreal Delivery of A190 loaded Microparticles in a Model of Age-related Macular Degeneration
Tuesday, July 15, 2025
3:16 PM - 3:27 PM EDT
Location: 123
Sponsored By
Introduction: Age-related macular degeneration (AMD) is a major global health challenge, causing vision impairment and compromised quality of life in the elderly population [1,2]. Therapeutic potential of peroxisome proliferator-activated receptor α (PPARα) agonists in retinal diseases is well-documented [3,4]. A190, a novel non-fibrate PPARα agonist, exhibits superior potency and selectivity for PPARα receptors [5]. This study aimed to assess the ocular pharmacokinetics of A190-MP and evaluate its efficacy in a murine model of dry AMD over a six-month period following a single intravitreal injection.
Learning Objectives:
At the completion of this activity, participants will know
Understand the role and therapeutic potential of PPARα agonists in treatment of retinal diseases.
Importance of sustained drug delivery strategies for the management of retinal diseases.
Yi Cui – Post doctoral researcher, Wake Forest University School of Medicine; Nuo Xu – Post doctoral researcher, Wake Forest University School of Medicine; Kelu Zhou – Research Scientist, Wake Forest University School of Medicine; Rui Cheng – Assistant Professor, Wake Forest University School of Medicine; Wentao Liang – Post doctoral researcher, Wake Forest University School of Medicine; Adam Duerfeldt – Associate Professor, University of Minnesota; Jian-xing Ma – Professor, Wake Forest University School of Medicine; Qingguo Xu – Associate Professor, Virginia Commonwealth University School of Pharmacy
